Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ricolinostat - Regenacy Pharmaceuticals

Drug Profile

Ricolinostat - Regenacy Pharmaceuticals

Alternative Names: ACY-1215; ACY-63; Rocilinostat

Latest Information Update: 28 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard University
  • Developer Columbia University; Dana-Farber Cancer Institute; Massachusetts General Hospital; Regenacy Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Hydroxamic acids; Pyrimidines; Small molecules
  • Mechanism of Action HDAC6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Multiple myeloma
  • Phase I/II Lymphoma
  • Phase I Breast cancer; Chronic lymphocytic leukaemia; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Preclinical Charcot-Marie-Tooth disease; Malignant melanoma; Peripheral nervous system diseases

Most Recent Events

  • 10 Apr 2021 Pharmacodynamics data from preclinical studies in Breast cancer presented at the 112the Annual Meeting of the American Association of Cancer Research (AACR-2021)
  • 07 Jan 2021 Biomarkers information updated
  • 21 Dec 2020 Regenacy Pharmaceuticals and 3E Bioventures Capital forms a joint venture, 3E-Regenacy Pharmaceuticals (BC Regenacy), for development of ricolinostat for Peripheral neuropathies in China, Hong Kong and Macau
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top